Erik Sulman named interim executive director at Duke Cancer Institute

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

Amid deepening controversy, Vinay Prasad, FDA’s top clinician and scientist, and director of its Center for Biologics Evaluation and Research, will be leaving the agency.

March 13, 2026

By Claire Marie Porter

In Brief

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Vivek Subbiah has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026.

March 13, 2026

In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

March 13, 2026

In Brief

GRAIL announces retirement of CEO Bob Ragusa, appoints President Josh Ofman as successor

GRAIL has announced that Bob Ragusa will retire as CEO, effective June 1.

March 13, 2026

In Brief

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

W. Kimryn Rathmell, CEO of the James Cancer Hospital and Solove Research Institute, has also been named director of The Ohio State University Comprehensive Cancer Center in place of former Director Raphael E. Pollock, who has stepped down from the position he had held since November 2017 to become OSUCCC director emeritus.

March 06, 2026

Vol.52 No.09